You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ivosidenib

Showing 1 - 17 of 17
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

IDH1-mutant Cholangiocarcinoma Trial (Ivosidenib, Recommended Combination Dose (RCD) of ivosidenib, Nivolumab)

Not yet recruiting
  • IDH1-mutant Cholangiocarcinoma
  • Ivosidenib
  • +3 more
  • (no location specified)
Jun 29, 2023

Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic Trial (Ivosidenib)

Not yet recruiting
  • Cholangiocarcinoma Non-resectable
  • Cholangiocarcinoma Metastatic
  • Ivosidenib
  • (no location specified)
Oct 10, 2023

Pancreatic Ductal Adenocarcinoma Trial in Cleveland (Ivosidenib, mFOLFIRINOX)

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Aug 15, 2022

Acute Myeloid Leukemia (AML) Trial in United States (Gilteritinib, Ivosidenib, Enasidenib)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • Basking Ridge, New Jersey
  • +6 more
Mar 3, 2023

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Decitabine and

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Decitabine and Cedazuridine
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2022

Clonal Cytopenia of Undetermined Significance Trial in United States (Ivosidenib)

Recruiting
  • Clonal Cytopenia of Undetermined Significance
  • Ivosidenib
  • Rochester, Minnesota
  • +5 more
Apr 4, 2022

Acute Myeloid Leukemia Trial in Houston (Decitabine and Cedazuridine, Enasidenib, Gilteritinib)

Recruiting
  • Acute Myeloid Leukemia
  • Decitabine and Cedazuridine
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 10, 2022

IDH1 Mutation Myeloid Tumors Trial in Baltimore, Boston, Columbus (Ivosidenib)

Active, not recruiting
  • IDH1 Mutation Myeloid Neoplasms
  • Ivosidenib
  • Baltimore, Maryland
  • +3 more
Oct 25, 2021

Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Unresectable Cholangiocarcinoma Trial in United States (Cisplatin,

Recruiting
  • Advanced Cholangiocarcinoma
  • +2 more
  • Scottsdale, Arizona
  • +7 more
Jun 24, 2022

Acute Myeloid Leukemia Trial in Columbus (Azacitidine, Biopsy, Enasidenib)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Jun 30, 2022

Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Tumor, Myelodysplastic Syndrome Trial in United States (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia
  • +5 more
  • Boston, Massachusetts
  • +3 more
Jun 30, 2021

IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation Trial in Chicago (Ivosidenib, Enasidenib, Fedratinib)

Recruiting
  • IDH Mutation
  • +4 more
  • Ivosidenib
  • +2 more
  • Chicago, Illinois
    University of Chicago Medical Center
Nov 12, 2021

Recurrent Acute Myeloid Leukemia Trial in Duarte (Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate)

Withdrawn
  • Recurrent Acute Myeloid Leukemia
  • Bosutinib Monohydrate
  • +6 more
  • Duarte, California
    City of Hope Meidcal Center
Jun 7, 2022

Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Tumor Trial in Chicago

Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • +4 more
  • Chicago, Illinois
    Northwestern University
Mar 26, 2021

Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma Trial in Puerto Rico, United States (Ivosidenib)

Recruiting
  • Recurrent Ependymoma
  • +32 more
  • Ivosidenib
  • Birmingham, Alabama
  • +173 more
Jan 27, 2023

Biliary Tract Tumors Trial in Belgium, France, United Kingdom (Futibatinib, Ivosidenib, Zanidatamab)

Not yet recruiting
  • Biliary Tract Neoplasms
  • Brussels, Belgium
  • +56 more
Nov 7, 2022

Cancer of Unknown Primary Site Trial in Worldwide (Alectinib, Vismodegib, Ipatasertib)

Active, not recruiting
  • Cancer of Unknown Primary Site
  • Blacktown, New South Wales, Australia
  • +140 more
Jan 6, 2023